FDA Advisory Committees Say Opana ER Benefits No Longer Outweigh Risks
Two FDA advisory committees voted Tuesday that the benefits of a previously approved formulation of Opana ER no longer outweigh the risks of abuse.
Source: Drug Industry Daily
Two FDA advisory committees voted Tuesday that the benefits of a previously approved formulation of Opana ER no longer outweigh the risks of abuse.
Source: Drug Industry Daily